TITLE

Cancer gene therapy update

AUTHOR(S)
Smith, J.A.; Goldspiel, B.R.
PUB. DATE
March 1999
SOURCE
Journal of Oncology Pharmacy Practice;Mar1999, Vol. 5 Issue 1, p7
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective. To provide an update about gene marking and gene therapy trials in cancer patients. Data Sources. A MEDLINE search using the term “gene therapy” was conducted for the period 1985 to 1998. The reference lists from retrieved articles were reviewed. Meeting abstracts from the American Society of Clinical Oncology annual meeting (published in their proceedings) and the Annual Cancer Gene Therapy Symposium (published in Cancer Gene Therapy) that concerned gene therapy in cancer patients were also included. Data Extraction. Both authors reviewed the retrieved material and included preclinical data, case reports, and clinical trials related to gene transfer or gene therapy in cancer patients. Data Synthesis. There are several possible approaches to using gene therapy for the diagnosis and treatment of cancer and for the monitoring of cancer therapy. Exogenous genes may be used to mark cells to help better understand cancer biology or may be used directly for cancer treatment. Gene-marking trials have already provided new information about cancer biology and have demonstrated that reinfused progenitor cells may be a source of relapse in patients with acute or chronic myelogenous leukemia and neuroblastoma. Approaches using gene therapy for cancer treatment include: using lymphocytes as gene carriers, using foreign genes to increase tumor immunogenicity, introducing tumor regression antigen genes into viruses, introducing “sensitivity” genes to produce new cytotoxic agent(s) within tumors, producing new protein product(s) to protect normal cells, replacing missing or mutant tumor suppressor genes, and inactivating oncogenes. Clinical trials using these strategies have demonstrated that gene transfer is feasible (albeit with low transduction efficiency) and that gene expression occurs; in addition, clinical responses have been noted.
ACCESSION #
5003786

 

Related Articles

  • Preclinical study on gene therapy of cervical carcinoma using adeno-associated virus vectors. Kunke, David; Grimm, Dirk; Denger, Stefanie; Kreuzer, Jörg; Delius, Hajo; Komitowski, Dymitr; Kleinschmidt, Jürgen A // Cancer Gene Therapy;May2000, Vol. 7 Issue 5, p766 

    Approximately 90% of cervical carcinomas are causally linked to infections with high-risk human papillomaviruses (HPVs), whose oncogenicity has been assigned to the continued expression of two early genes, E6 and E7. Reversal of the transformed phenotype by inhibiting E6/E7 gene expression...

  • Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: Consequences for anti-cancer gene therapy. Hoshi, Michio; Harada, Asako; Kawase, Takeshi; Uyemura, Keiichi; Yazaki, Takahito // Cancer Gene Therapy;May2000, Vol. 7 Issue 5, p799 

    We set up experiments to evaluate the effects of defective herpes simplex virus (HSV)-mediated in vitro gene transfer of tissue inhibitor of metalloproteinases-2 (TIMP-2) in malignant glioma cells. Intrinsic TIMPs are known to be inhibitors of the strong invasive activities of matrix...

  • 774. Evaluation of Adenovirus Vectors Containing Serotype 35 Fibers for Gene Therapy of Cervical Cancer. Ying Liu; Sova, Pavel; Strauss, Robert; Tuve, Sebastian; Morihara, Janice; Kiviat, Nancy; Toure, Papa; Sow, Salif; Lieber, Andre // Molecular Therapy;Jun2006, Vol. 13, pS299 

    Adenovirus vectors containing group B fibers (such as Ad5/35) are able to target tissues that are refractory to infection with commonly used Ad serotype 5 based vectors. To evaluate the utility of Ad5/35 vectors for gene transfer into tumor cells, we studied the expression of the Ad5 receptor,...

  • 534. Silk-Elastinlike Polymers for Matrix-Mediated Adenoviral Gene Delivery. Hatefi, Arash; Ghandehari, Hamid // Molecular Therapy;Jun2006, Vol. 13, pS205 

    INTRODUCTIONMatrix-mediated polymeric gene delivery can reduce administration frequency and toxicity while maximizing efficacy of cancer gene therapy. Here we report the release and bioactivity of Ad.CMV-GFP from silk-elastinlike polymers (SELPs) hydrogels. We hypothesize that by genetic...

  • 922. Improvement of Anti-Tumor Activity by Gene Amplification with a Replicative, Non-Disseminative Adenovirus. Lau, Cara J.; Bourbeau, Denis; Jaime, Jairo; Nalbantoglu, Josephine; Massie, Bernard // Molecular Therapy;Jun2006, Vol. 13, pS356 

    Gene therapy is a promising approach for cancer treatment; however efficacy of current vectors remains insufficient. In this study, we aimed to improve the success of suicide gene transfer by utilizing a replication competent vector that increases transgene copy number, improves gene expression,...

  • Oncology. Karp, Judith E.; Broder, Samuel // JAMA: Journal of the American Medical Association;6/19/91, Vol. 265 Issue 23, p3141 

    Presents updates on oncology as of June 2001. Application of the principles of molecular biology to the care of patients with cancer; Evolution of gene therapy in human disease; Gene transfer in the study of melanoma.

  • Gene Transfer: Bax to the future for cancer therapy. Lemoine, N R; McNeish, I A // Gut;Apr2004, Vol. 53 Issue 4, p478 

    Malignant disease localized within the abdominal cavity has been a target for the staged development of clinical gene therapy approaches because of the smaller doses of experimental agent and increased safety margins over systemic administration. The article focuses on the Bax gene as a...

  • Nonviral Vectors for Cancer Gene Therapy: Prospects for Integrating Vectors and Combination Therapies. Ohlfest, John R.; Freese, Andrew B.; Largaespada, David A. // Current Gene Therapy;Dec2005, Vol. 5 Issue 6, p629 

    Gene therapy has the potential to improve the clinical outcome of many cancers by transferring therapeutic genes into tumor cells or normal host tissue. Gene transfer into tumor cells or tumor-associated stroma is being employed to induce tumor cell death, stimulate anti-tumor immune response,...

  • Stable inhibition of human thymidylate synthase expression following retroviral introduction of an siRNA gene. Yang, Z.; Cloud, A.; Hughes, D.; Johnson, L. F. // Cancer Gene Therapy;Jan2006, Vol. 13 Issue 1, p107 

    Thymidylate synthase (TS) is an essential enzyme that synthesizes thymidylic acid in the de novo biosynthetic pathway. Inhibiting TS enzyme activity with substrate or cofactor analogs leads to inhibition of DNA replication and cell death. For this reason, TS is an important target enzyme for...

  • Where we stand with gene therapy for bladder cancer. Zhiping Wang; Matsumoto, Kazumaza; Lerner, Seth; Rodriguez, Ronald // Contemporary Urology;Sep2004, Vol. 16 Issue 9, p28 

    Discusses gene transfer methodologies for the treatment of recalcitrant carcinoma in situ of the bladder and muscle-invasive disease. Percentage of patients treated for superficial disease develop recurrence and progress to more aggressive disease; Three areas for gene therapy; Limitations of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics